36834781|t|Phospholipase D1 Attenuation Therapeutics Promotes Resilience against Synaptotoxicity in 12-Month-Old 3xTg-AD Mouse Model of Progressive Neurodegeneration.
36834781|a|Abrogating synaptotoxicity in age-related neurodegenerative disorders is an extremely promising area of research with significant neurotherapeutic implications in tauopathies including Alzheimer's disease (AD). Our studies using human clinical samples and mouse models demonstrated that aberrantly elevated phospholipase D1 (PLD1) is associated with amyloid beta (Abeta) and tau-driven synaptic dysfunction and underlying memory deficits. While knocking out the lipolytic PLD1 gene is not detrimental to survival across species, elevated expression is implicated in cancer, cardiovascular conditions and neuropathologies, leading to the successful development of well-tolerated mammalian PLD isoform-specific small molecule inhibitors. Here, we address the importance of PLD1 attenuation, achieved using repeated 1 mg/kg of VU0155069 (VU01) intraperitoneally every alternate day for a month in 3xTg-AD mice beginning only from ~11 months of age (with greater influence of tau-driven insults) compared to age-matched vehicle (0.9% saline)-injected siblings. A multimodal approach involving behavior, electrophysiology and biochemistry corroborate the impact of this pre-clinical therapeutic intervention. VU01 proved efficacious in preventing in later stage AD-like cognitive decline affecting perirhinal cortex-, hippocampal- and amygdala-dependent behaviors. Glutamate-dependent HFS-LTP and LFS-LTD improved. Dendritic spine morphology showed the preservation of mushroom and filamentous spine characteristics. Differential PLD1 immunofluorescence and co-localization with Abeta were noted.
36834781	0	16	Phospholipase D1	Gene	18805
36834781	70	85	Synaptotoxicity	Disease	
36834781	102	106	3xTg	Disease	
36834781	107	109	AD	Disease	MESH:D000544
36834781	110	115	Mouse	Species	10090
36834781	137	154	Neurodegeneration	Disease	MESH:D019636
36834781	167	182	synaptotoxicity	Disease	
36834781	186	225	age-related neurodegenerative disorders	Disease	MESH:D019636
36834781	319	330	tauopathies	Disease	MESH:D024801
36834781	341	360	Alzheimer's disease	Disease	MESH:D000544
36834781	362	364	AD	Disease	MESH:D000544
36834781	385	390	human	Species	9606
36834781	412	417	mouse	Species	10090
36834781	463	479	phospholipase D1	Gene	5337
36834781	481	485	PLD1	Gene	5337
36834781	506	518	amyloid beta	Gene	351
36834781	520	525	Abeta	Gene	351
36834781	542	562	synaptic dysfunction	Disease	MESH:C536122
36834781	578	593	memory deficits	Disease	MESH:D008569
36834781	628	632	PLD1	Gene	5337
36834781	722	728	cancer	Disease	MESH:D009369
36834781	730	755	cardiovascular conditions	Disease	MESH:D002318
36834781	760	776	neuropathologies	Disease	MESH:D009422
36834781	844	847	PLD	Gene	2822
36834781	927	931	PLD1	Gene	18805
36834781	980	989	VU0155069	Chemical	MESH:C585271
36834781	991	995	VU01	Chemical	MESH:C585271
36834781	1050	1054	3xTg	Disease	
36834781	1055	1057	AD	Disease	MESH:D000544
36834781	1058	1062	mice	Species	10090
36834781	1360	1364	VU01	Chemical	MESH:C585271
36834781	1413	1415	AD	Disease	MESH:D000544
36834781	1421	1438	cognitive decline	Disease	MESH:D003072
36834781	1516	1525	Glutamate	Chemical	MESH:D018698
36834781	1681	1685	PLD1	Gene	18805
36834781	1730	1735	Abeta	Gene	11820
36834781	Negative_Correlation	MESH:C585271	MESH:D003072
36834781	Association	MESH:D008569	5337
36834781	Association	11820	18805
36834781	Positive_Correlation	MESH:C585271	MESH:D018698
36834781	Negative_Correlation	MESH:C585271	18805
36834781	Positive_Correlation	351	5337
36834781	Association	MESH:D009422	5337
36834781	Association	MESH:D002318	5337
36834781	Association	MESH:C536122	5337
36834781	Negative_Correlation	MESH:C585271	MESH:D000544
36834781	Association	MESH:D009369	5337

